Maze Therapeutics CEO reports 31,908-share trust sale
Maze Therapeutics CEO Jason V. Coloma sold 34,501 shares of the company's stock through two trusts, totaling approximately $932,000. The sales were made under a pre-arranged Rule 10b5-1 trading plan at weighted average prices of $27.0241 and $27.0210 per share, respectively. The transactions occurred on October 1, 2026, with the trusts retaining significant holdings afterward.
How this was made
The 30-second read
Why it matters
The disclosed sales total under $1M, representing a routine insider transaction with limited market impact.
Market read
A modest insider sale that may cause slight short‑term pressure but is unlikely to move the stock significantly.
What to watch
Potential tax planning or liquidity needs unrelated to company fundamentals.
Background
Maze Therapeutics filed a Form 4 reporting insider sales by the CEO's trusts under a pre‑established 10b5-1 plan.
Ticker impact
CEO Jason V. Coloma sold 31,908 shares of Maze Therapeutics from his family trust under a 10b5-1 plan, valued at about $862K.
likely slight downward pressure as the market prices in the insider sale
The transaction is a routine 10b5-1 sale of less than $1M, which typically has limited impact but can signal insider confidence levels.
Market effects
Minimal; the sale does not affect the broader biotech sector.
None; confined to Maze Therapeutics investors.
Low
Counterpoint
The sale could be interpreted as a lack of confidence, prompting a short‑term dip.
Key entities
- personJason V. Coloma
CEO and director of Maze Therapeutics, seller of the shares.
- companyMaze Therapeutics, Inc.
Biotech firm listed on NASDAQ under ticker MAZE.
